CAR-NK cell therapy - Cellinfinity Bio
Alternative Names: CIB-F1-N-Cellinfinity BioLatest Information Update: 03 Mar 2023
At a glance
- Originator Cellinfinity Bio
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours